• BioNexus set 2026 targets to deploy the VitaGuard MRD liquid-biopsy platform in select Southeast Asian medical hubs, subject to local approvals.
• Planning is underway to transfer and localize operating documentation, then complete laboratory verification and validation in Malaysia and Singapore.
• Execution will run under an exclusive license covering 10 Southeast Asian markets, with sublicensing permitted only with Fidelion’s prior written consent.
• Management continues to plan for a cost per test below USD 300 before local pricing and reimbursement considerations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-004556), on July 28, 2026, and is solely responsible for the information contained therein.